January 29, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street NE
Washington, D.C. 20549
Attention: Alan Campbell
Re: | BriaCell Therapeutics Corp. |
Registration Statement on Form S-3 | |
File No. 333-276650 | |
Filed January 22, 2024 |
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), BriaCell Therapeutics Corp. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective date of the above-referenced registration statement (the “Registration Statement”) so as to become effective on Wednesday, January 31, 2024, at 5:00 p.m. Eastern Time, or as soon thereafter as practicable. Once the Registration Statement has been declared effective, please confirm orally that event with our counsel, Sichenzia Ross Ference Carmel LLP, by calling Avital Perlman, Esq. at 212-930-9700.
Very truly yours, | |
/s/ William V. Williams | |
William V. Williams Chief Executive Officer |